Reversible Disulfide Formation of the Glutamate Carboxypeptidase II Inhibitor E2072 Results in Prolonged Systemic Exposures In Vivo

E2072 [(3-2-mercaptoethyl)biphenyl-2,3′-dicarboxylic acid] is a novel, potent and selective thiol-based glutamate carboxypeptidase II (GCP-II) inhibitor that has shown robust analgesic and neuroprotective efficacy in preclinical models of neuropathic pain and chemotherapy-induced peripheral neuropathy. For the first time, we describe the drug metabolism and pharmacokinetic profile of E2072 in rodents and primates. Intravenously administered E2072 was found to exhibit an unexpectedly long terminal half-life (105 ± 40 h) in rats. The long half-life was found to be the result of its ability to rapidly form reversible homo- and possibly heterodisulfides that served as a continuous E2072 depot. The half-life of reversible homodisulfides was 208 ± 81 h. In further support, direct intravenous administration of the E2072-homodisulfide in rats resulted in the formation of E2072, with both E2072 and its disulfide detected in plasma up to 7 days after dose. The observed long exposures were consistent with the sustained efficacy of E2072 in rodent pain models for several days after dose cessation. It is noteworthy that a shorter t1/2 of E2072 (23.0 ± 1.2 h) and its homodisulfide (21.0 ± 0.95 h) was observed in primates, indicating interspecies differences in its disposition. In addition, E2072 was found to be orally available with an absolute bioavailability of ∼30% in rats and ∼39% in monkeys. A tissue distribution study of E2072 and its homodisulfide in rats showed good tissue penetration, particularly in sciatic nerve, the presumed site of action for treatment of neuropathy. Metabolic stability and the correlation between pharmacokinetic profile and pharmacological efficacy support the use of this GCP-II inhibitor in the clinic.

[1]  D. Ferraris,et al.  Design, synthesis, and pharmacological evaluation of glutamate carboxypeptidase II (GCPII) inhibitors based on thioalkylbenzoic acid scaffolds. , 2012, Journal of medicinal chemistry.

[2]  B. Slusher,et al.  The role of glutamate signaling in pain processes and its regulation by GCP II inhibition. , 2012, Current medicinal chemistry.

[3]  G. Cavaletti,et al.  Tissue distribution of glutamate carboxypeptidase II (GCPII) with a focus on the central and peripheral nervous system. , 2012, Current medicinal chemistry.

[4]  A. Kaplin,et al.  Glutamate in CNS neurodegeneration and cognition and its regulation by GCPII inhibition. , 2012, Current medicinal chemistry.

[5]  M. Pomper,et al.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. , 2012, Current medicinal chemistry.

[6]  Haishan Wang,et al.  Preclinical Metabolism and Disposition of SB939 (Pracinostat), an Orally Active Histone Deacetylase Inhibitor, and Prediction of Human Pharmacokinetics , 2011, Drug Metabolism and Disposition.

[7]  D. Giustarini,et al.  Detection of glutathione in whole blood after stabilization with N-ethylmaleimide. , 2011, Analytical biochemistry.

[8]  J. Neale,et al.  Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family , 2011, Journal of neurochemistry.

[9]  Hannah M Jones,et al.  Preclinical and Clinical Pharmacokinetics of PF-02413873, a Nonsteroidal Progesterone Receptor Antagonist , 2011, Drug Metabolism and Disposition.

[10]  V. Venditti,et al.  A structurally driven analysis of thiol reactivity in mammalian albumins. , 2011, Biopolymers.

[11]  G. Cavaletti,et al.  Glutamate Carboxypeptidase Inhibition Reduces the Severity of Chemotherapy-Induced Peripheral Neurotoxicity in Rat , 2010, Neurotoxicity Research.

[12]  Kenji Tabata,et al.  A Comparison of Pharmacokinetics between Humans and Monkeys , 2010, Drug Metabolism and Disposition.

[13]  Z. Xi,et al.  N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats , 2010, Neuropharmacology.

[14]  Z. Xi,et al.  Inhibition of NAALADase by 2‐PMPA attenuates cocaine‐induced relapse in rats: a NAAG‐mGluR2/3‐mediated mechanism , 2010, Journal of neurochemistry.

[15]  Rikiya Ohashi,et al.  Effect of Plasma Protein Binding on in Vitro-in Vivo Correlation of Biliary Excretion of Drugs Evaluated by Sandwich-Cultured Rat Hepatocytes , 2008, Drug Metabolism and Disposition.

[16]  A. Sima,et al.  The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy , 2006, Journal of the Neurological Sciences.

[17]  J. Luszczki,et al.  2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. , 2006, European journal of pharmacology.

[18]  J. Neale,et al.  The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. , 2005, Trends in pharmacological sciences.

[19]  D. Hilt,et al.  The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. , 2005, British journal of clinical pharmacology.

[20]  A. Bodner,et al.  Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Qun Liu,et al.  Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. , 2003, Journal of medicinal chemistry.

[22]  A. Zapata,et al.  NAALADase (GCP II) inhibition prevents cocaine-kindled seizures , 2002, Neuropharmacology.

[23]  A. Sima,et al.  GCPII (NAALADase) Inhibition Prevents Long‐Term Diabetic Neuropathy In Type 1 Diabetic BB/WOR Rats , 2002 .

[24]  T. Tsukamoto,et al.  Phosphonate and phosphinate analogues of N-acylated gamma-glutamylglutamate. potent inhibitors of glutamate carboxypeptidase II. , 2002, Bioorganic & medicinal chemistry letters.

[25]  H. Pan,et al.  Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. , 2002, The Journal of pharmacology and experimental therapeutics.

[26]  X. C. Lu,et al.  Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. , 2001, Journal of medicinal chemistry.

[27]  Tatsuo Yamamoto,et al.  Spinal N-acetyl-α-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat , 2001, Brain Research.

[28]  T. Yamamoto,et al.  Inhibition of spinal N-acetylated-α-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test , 2001, Neuroscience.

[29]  K. Wada,et al.  N-acetylated-α-linked-acidic dipeptidase inhibitor has a neuroprotective effect on mouse retinal ganglion cells after pressure-induced ischemia , 2000, Neuroscience Letters.

[30]  F. Tortella,et al.  Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury , 1999, Nature Medicine.

[31]  J. Coyle,et al.  Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization. , 1990, The Journal of biological chemistry.

[32]  R. Waring,et al.  The metabolism and disposition of D-penicillamine in the DA-strain rat , 1988, European Journal of Drug Metabolism and Pharmacokinetics.

[33]  Gary J. Bennett,et al.  A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man , 1988, Pain.

[34]  R. Dubner,et al.  A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia , 1987, Pain.

[35]  O. Drummer,et al.  Effect of probenecid on the disposition of captopril and captopril dimer in the rat. , 1985, Biochemical pharmacology.

[36]  H. Takashina,et al.  [Study on metabolism of the dithiol compound. I. Isolation and identification of metabolites of N-(2-mercapto-2-methylpropanoyl)-L-cysteine (SA96) in the blood and urine of the rat]. , 1985, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[37]  M. Kuwano,et al.  [Pharmacological studies of N-(2-mercapto-2-methylpropionyl)-L-cysteine (SA 96). VI. Effects on vitamin B6, metals and skin collagen in rats]. , 1985, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[38]  P. Worland,et al.  Gastric and intestinal absorption of captopril in acutely and chronically treated rats: comparison with salicylic acid. , 1984, Journal of pharmaceutical sciences.

[39]  O. Drummer,et al.  Captopril disulfide conjugates may act as prodrugs: disposition of the disulfide dimer of captopril in the rat. , 1984, Biochemical pharmacology.

[40]  J. Miners,et al.  Reversible metabolism of D-penicillamine in the rat. , 1984, Drug Metabolism And Disposition.

[41]  A. Breckenridge,et al.  Drug protein conjugates--VI. Role of glutathione in the metabolism of captopril and captopril plasma protein conjugates. , 1983, Biochemical pharmacology.

[42]  原田 知加子.  N-acetylated-α-linked-acidic dipeptidase inhibitor has a neuroprotective effect on mouse retinal ganglion cells after pressure-induced ischemia , 2001 .